Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 183

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 8
Chunk 183
---

    )

    Cash flows from investing activities:

    Purchases of equipment

    —

    (73,561
    )

    Net cash used in investing activities

    —

    (73,561
    )

    Cash flows from financing activities:

    Proceeds from issuance of related party note

    5,000,000

    —

    Proceeds from sale of shares in private placement

    5,800,000

    —

    Purchase of treasury shares to satisfy tax withholdings

    —

    (477,639
    )

    Proceeds from employee stock purchases and option exercises

    19,986

    70,466

    Net cash provided by (used in) financing activities

    10,819,986

    (407,173
    )

    Effect of exchange rate changes on cash

    (54,699
    )

    (25,250
    )

    Net increase (decrease) in cash

    1,209,811

    (16,268,496
    )

    Cash, beginning of period

    3,367,229

    19,635,725

    Cash, end of period
     
    $
    4,577,040

    $
    3,367,229

    Supplemental cash flow information:

    Cash paid for interest
     
    $
    13,135

    $
    27,509

    Supplemental disclosures - non-cash activities:

    Insurance financing agreement
     
    $
    172,000

    $
    109,000

    Issuance of stock options for payment of certain employee bonuses

    1,031,908

    —

    Issuance of related party note (Note 10)

    792,878

    —

    Issuance of common stock, $0.00001 par value, for payment of employee bonuses

    —

    1,011,360

    Issuance of common stock, $0.00001 par value, in connection with payment for services

    —

    30,000

See accompanying notes to consolidated financial statements. 

 73

MiNK THERAPEUTICS, INC. AND SUBSIDIARIES